Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.

Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.

Item

http://www.wikidata.org/entity/Q34417423

Q34417423

about

Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors Determination of sunitinib and its active metabolite, N-desethyl sunitinib in mouse plasma and tissues by UPLC-MS/MS: assay development and application to pharmacokinetic and tissue distribution studies.Simultaneous determination of erlotinib and its isomeric major metabolites in human plasma using isocratic liquid chromatography-tandem mass spectrometry and its clinical application.Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives.Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma.Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer A stable isotope-labeled internal standard is essential for correcting for the interindividual variability in the recovery of lapatinib from cancer patient plasma in quantitative LC-MS/MS analysis.Clinical development of imatinib: an anticancer drug.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.Mass spectrometry in leukemia research and treatment.Antineoplastic drugs and their analysis: a state of the art review.Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies.Development and application of an HPLC method for erlotinib protein binding studies.Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients.A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma.Novel therapeutic modalities and drug delivery - erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations.Determination of sunitinib in human plasma using liquid chromatography coupled with mass spectrometry.Fast quantitative analysis of four tyrosine kinase inhibitors in different human plasma samples using three-way calibration-assisted liquid chromatography with diode array detection.Ultrasound assisted dispersive micro solid-phase extraction of four tyrosine kinase inhibitors from serum and cerebrospinal fluid by using magnetic nanoparticles coated with nickel-doped silica as an adsorbent

P2860

Q28236180-76445175-B954-4AE4-83E1-CD500760B0E6 Q35311474-52A4067A-FFE2-4DCF-9A56-70BF43D73433 Q35313647-E64D1079-4C6E-46AE-A482-6F29B666633E Q35450340-16F3E09D-9A6F-41F8-8BD9-3FC64AA2C0B5 Q35829430-E2257252-D047-4E02-8159-8B398AE2CD29 Q36083906-23528828-06F0-4E7C-9AFA-6814A0D376AF Q36289916-27DA0B97-2A78-4B06-B9B4-C98E761D6585 Q37358418-E927250B-9C33-4DCB-B1D5-5B75348373D0 Q37474460-2D7CFC68-763F-4F08-9607-92D46EBE0A86 Q38201503-661E1AAC-7179-4495-B3AC-BC3DB689C066 Q38365432-01F64AEA-BEA7-456A-A8B8-204965BCEB20 Q39339684-626BC55E-FA95-4305-B5D7-C36343709C3D Q41853401-1F47F6CB-894E-4510-BDDD-A87AE32A765F Q42012916-86D0F660-2D62-4087-A748-F2CC37AA4123 Q48152547-E5259F77-A22A-42D7-86FF-CFE1AF05B3ED Q49473156-E26DE65E-FC27-4A8A-97A2-AB1966A2917E Q50224629-EF7F3506-311F-4DEC-ADFF-4941659899D4 Q50465014-304E7A0D-184D-4321-9D66-34B2D259D047 Q53489856-ECB9D4C1-0083-4305-9198-BD65901B4531 Q58752788-A758A8DB-312C-4E09-83C5-21E1045DC1BF

P2860

Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.

Item

http://www.wikidata.org/entity/Q34417423

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu